Open AccessCombinatorial therapy of sirolimus and heparin by nanocarrier inhibits restenosis after balloon angioplasty ex vivo
Author(s) -
Jayesh V Betala,
Sooneon Bae,
Eugene M. Langan,
Martine LaBerge,
Jeoung Soo Lee
Publication year - 2020
Publication title -
nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.947
H-Index - 109
eISSN - 1748-6963
pISSN - 1743-5889
DOI - 10.2217/nnm-2020-0028
Subject(s) - restenosis , angioplasty , ex vivo , sirolimus , in vivo , balloon , coronary arteries , heparin , medicine , artery , chemistry , cardiology , in vitro , stent , biology , biochemistry , microbiology and biotechnology
Aim: To develop poly(lactide-co-glycolide)-graft-polyethylenimine (PgP) as a dual drug-delivery carrier for sirolimus (SR) and heparin (Hep) to inhibit restenosis after balloon angioplasty. Materials & methods: SR was loaded in the hydrophobic core and negatively charged Hep complexed with the positively charged hydrophilic shell of PgP. SR- and Hep-loaded PgP was tested on rat aortic smooth muscle cells in vitro and injured porcine coronary arteries after balloon angioplasty ex vivo . Results & conclusion: SR and Hep loading efficiency in PgP were approximately 37 and 82%, respectively. SR- and Hep-loaded PgP treatment decreased smooth muscle cell proliferation up to 14 days post-treatment and decreased proliferation, collagen deposition and neointimal thickness and increased patency in porcine coronary arteries after balloon angioplasty ex vivo .